- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02139839
Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14
May 13, 2014 updated by: Kimberly-Clark Corporation
A Single-Center Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14 on Subjects With Intermediate Nugent Scores
The purpose of this study was to determine whether L. rhamnosus GR-1 and L. reuteri RC-14 delivered via capsules to the vagina of post-menopausal women over a three day course of treatment can restore and maintain a lactobacilli-dominated microbiota.
Exploratory analysis of microbial ecology, human microarrays and multiplex immunological assessments are included to characterize potential effects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6J 0A8
- Dorli Herman
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Willing and able to read, understand, and sign the Informed Consent Form (ICF);
- Post-menopausal females between the ages of 40 and 80 years old (subjects who have not had a menstrual period for the last 12 months);
- Currently in a mutually monogamous sexual relationship or not sexually active;
- Agree to be sexually abstinent 72 hours prior to each study visit. Also, agree to refrain from intercourse for 48 hours after treatment administration;
- Agree to abstain from the use of any other intravaginal product (e.g. gels, foams, lubricants, douches, etc.) throughout the study period, from the time of screening until Day 47;
- Willing and capable of following all study instructions; and
- Good general health.
Exclusion Criteria:
- Use of vaginal lubricants, or any products applied vaginally within three months prior to Visit 1and throughout the duration of study participation;
- A history or currently undergoing immunosuppressive drug therapy, chemotherapy, or radiation therapy;
- A medical condition which might compromise immune system functions (such as cancer, leucopenia, HIV-positive, or organ transplant);
- Antibiotics and/or antifungal medication use within the last four (4) weeks;
- Oral probiotic supplement use within 3 months prior to Visit 1 and throughout the duration of the study;
- Significant changes in diet during the course of the study based on self-report;
- Induced menopause due to surgical or medical interventions, such as bilateral oophorectomy, hysterectomy, chemotherapy or radiation treatment;
- Currently undergoing local or systemic estrogen therapy who are not willing to alter therapy during the course of the study;
- A Nugent Score of 0 - 3 or greater than 6;
- History of drug or alcohol abuse;
- Currently diagnosed with or being treated for a genital infection or urinary tract infection;
- Individuals with a sexually transmitted disease (self-reported or detected by the Principal Investigator);
- At enrollment, have any social or medical condition, or psychiatric illness that, in the opinion of the Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives;
- Participation in a clinical trial involving an investigational product/device within the past three months; subjects who are scheduled to participate in another clinical study concurrently; and
- Known intolerance or allergy to L. rhamnosus GR-1® or L. reuteri RC-14® or to any product excipients.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Gelatin pill first
|
L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr.
Hansen
Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
|
Experimental: Lactobacillus capsules first
|
L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr.
Hansen
Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline Nugent Score (arbitrary units) after treatment versus Change from baseline Nugent Score after placebo
Time Frame: Baseline Days 15 & 36, post treatment/control Days 19 & 40
|
Determine whether L. rhamnosus GR-1 and L. reuteri RC-14 delivered via capsules to the vagina of post-menopausal women over a three day course of treatment can restore and maintain a lactobacilli-dominated microbiota for one week as measured by a decrease in the Nugent Scores from an intermediate score (4 - 6) at baseline to a normal score (0 - 3) following treatment compared to a placebo.
|
Baseline Days 15 & 36, post treatment/control Days 19 & 40
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Lactobacilli abundance
Time Frame: Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Change in lactobacilli abundance before and after probiotic treatment and before and after placebo treatment.
Lactobacilli abundance will be calculated as percentage of number of lactobacilli taxon divided by the total number of taxons.
|
Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Change in presence of metabolites
Time Frame: Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Gas chromatography-mass spectrometry will be used to determine changes in metabolites (such as lactate, glutamic acid, and others) before and after probiotic and placebo treatments.
|
Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Change in cytokine/chemokine levels
Time Frame: Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Multiplex ELISA based assay will be used to evaluate the modulation of cytokine and chemokine levels known regulate inflammation and host defense response before and after probiotic and placebo treatment.
|
Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Change in global host gene expression
Time Frame: Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Microarray analysis using GeneChip Human 2.0 ST array will be used to measure gene expression changes (by mRNA analysis) to determine whether there are differences in gene regulation between probiotic, placebo, and no treatment conditions.
|
Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Change in self-reported vaginal symptoms
Time Frame: Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Symptom analysis to evaluate whether probiotic treatment is associated with symptom relief.
|
Untreated (Days 1, 5, & 15), Baseline Treatment I (Days15), Treatment I (Days 19 & 26), Baseline Treatment II (Day 36), Treatment II (Days 40 & 47)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
May 1, 2013
Study Registration Dates
First Submitted
May 2, 2014
First Submitted That Met QC Criteria
May 13, 2014
First Posted (Estimate)
May 15, 2014
Study Record Updates
Last Update Posted (Estimate)
May 15, 2014
Last Update Submitted That Met QC Criteria
May 13, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 500-10-0002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaginosis, Bacterial
-
Alfasigma S.p.A.ParexelTerminatedBACTERIAL VAGINOSISUnited States
-
CDA Research Group, Inc.TerminatedBacterial Vaginosis (BV)United States
-
University of Alabama at BirminghamWayne State UniversityCompletedRecurrent Bacterial VaginosisUnited States
-
Zagazig UniversityUnknownBacterial Vaginosis TreatmentEgypt
-
Unity Health TorontoCompleted
-
Zagazig UniversityRecruitingBacterial Vaginosis | Vaginal | MicrobiologyEgypt
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
Mount Sinai Hospital, CanadaUnity Health TorontoCompletedPregnant Women Who Test Positive for Bacterial VaginosisCanada
-
Kaiser PermanenteWithdrawnRecurrent Bacterial VaginosisUnited States
-
Universiti Kebangsaan Malaysia Medical CentreNot yet recruitingBacterial Vaginoses
Clinical Trials on Lactobacillus capsules
-
Sahlgrenska University Hospital, SwedenBioGaia ABCompleted
-
Ain Shams UniversityRecruiting
-
SunWay Biotech Co., LTD.RecruitingOverweight | Body Weight | Body FatTaiwan
-
Western University, CanadaCompletedBacterial Vaginosis | Vulvovaginal CandidiasisRwanda
-
The First Affiliated Hospital with Nanjing Medical...RecruitingBreast Cancer FemaleChina
-
GenMont Biotech IncorporationBiomedical Development CorporationCompletedProbiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)Taiwan
-
Tianjin Medical University Second HospitalRecruitingBladder Urothelial CarcinomaChina
-
Evangelos J. Giamarellos-Bourboulis, M.D.Aristotle University Of ThessalonikiCompletedPostoperative Complications
-
The Affiliated Hospital of Qingdao UniversityQilu Hospital of Shandong University; Shandong Provincial Hospital; Shandong... and other collaboratorsRecruitingGastric Cancer | Neoadjuvant ChemotherapyChina
-
Beijing Friendship HospitalRecruitingRole and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's DiseaseBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson Disease | Parkinsonian Disorders | Basal Ganglia Diseases | Movement Disorders | Neurodegenerative DiseasesChina